Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated 49% lower of nephrolithiasis compared GLP-1 receptor agonists.
 Aim: we examined the association between and empagliflozin, using existing data from randomized clinical trials.
 Methods: pooled 15 081 T2D to empaglif...

INTRODUCTION Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose cotransporter 2 (SGLT2) inhibitors and their use in patients with HF. Data on the effect of SGLT2 inhibitor use with diuretics are limited. We hypothesise that SGLT2 inhibition may augment the effects of loop d...

BACKGROUND Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line treatment after the failure of metformin. However, SUs are associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor in development for the treatment of T2DM. In Phase II/III trials, empagliflozin reduced hyp...

Abstract: Type 2 diabetes mellitus (T2DM) is the most common type of today. Lifestyle changes are one causes DM problems. Patients with T2DM usually treated oral hypoglycemic drugs. The sodium glucose cotransporter (SGLT-2) group a drug groups that plays role in reducing HbA1c level. Empagliflozin included SGLT-2 group. Previous clinical trials showed empagliflozin could lead to reduction This ...

Peripheral artery disease (PAD) is one of the most common cardiovascular complications in patients with type 2 diabetes mellitus (T2DM)1 and is a predictor of cardiovascular death.2 Interventions that reduce cardiovascular complications in this patient population are urgently required. In the EMPA-REG OUTCOME trial, the sodium glucose cotransporter 2 inhibitor empagliflozin reduced the risk of ...

In patients with heart failure, empagliflozin offers significant cardiovascular benefits. However, its exact mode of action is unknown. Understanding the way by which works in failure may uncover additional therapeutic targets or identify other classes drugs that be useful to clinicians and patients. This literature review aims unravel mysteries reduces death, events, hospitalization diabetic n...

Background: Sotalol is a class III antiarrhythmic drug commonly used in various arrhythmia treatments. However, due to its potent potassium channel inhibition, it can prolong the QT interval and lead malignant arrhythmias. Empagliflozin an inhibitor of sodium‑glucose cotransporter 2 (SGLT2) has positive effect on cardiovascular outcomes. Since empagliflozin activation channels unknown, there no...